NCT04442724View on ClinicalTrials.gov

Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Bladder CancerUrinary Bladder NeoplasmUrologic NeoplasmsNeoplasmsUrinary Bladder Diseases
Interventions
PROCEDURE

Fiducial marker placement

placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection

DIAGNOSTIC_TEST

Multiparametric MRI (mpMRI)

In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.

Trial Locations (3)

90048

RECRUITING

Cedars-Sinai Medical Center (CSMC), Los Angeles

90095

RECRUITING

University of California Los Angeles, Los Angeles

02114

RECRUITING

Harvard School of Medicine/Massachusetts General Hospital (MGH), Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Cedars-Sinai Medical Center

OTHER